Remdesivir is an existing antiviral treatment that, awaiting completion of clinical trials, has shown promising results for treating coronavirus. The pharmaceutical company Gilead has the patent for the drug in more than 70 countries, and could block the entry of generics until 2031.
That’s why more than 150 organizations and personalities around the world have sent this letter to Daniel O’Day, CEO of Gilead, asking him for immediate action to ensure the availability, affordability and accessibility of remdesivir.
You can read the letter here or by clicking on this image:
Photo:31 Sundry Photography / Shutterstock
